FDA Cracks Down on GLP-1 Compounding Pharmacies in US
⢠FDA announced new enforcement actions targeting compounding pharmacies producing GLP-1 drugs like semaglutide amid safety concerns. ⢠The crackdown addresses risks from unapproved versions of weight-loss and diabetes medications flooding the market. ⢠This policy shift aims to protect patients from potential contamination and dosing errors in the booming $100 billion GLP-1 sector.
ama-assn.org